TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04005417
Drug: Stannous fluoride dentifrice
Normalized name: Stannous Fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride (0.454%) dentifrice
Study: NCT04005417
Drug: Positive control dentifrice
Normalized name: sodium fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive control dentifrice containing potassium nitrate or arginine.
Study: NCT04005417
Drug: Negative control dentifrice
Normalized name: sodium fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study: NCT02370680
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: steady-state run-in prior to Durlaza treatment
Study: NCT00722956
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one single dose of 40 mg on day 10
Study: NCT01763606
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
Study: NCT01763606
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
Study: NCT03475589
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
Study: NCT00042406
Drug: HuMax-CD4
Normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
Study: NCT00042406
Drug: Humax-CD4
Normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
Study: NCT00564018
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage adjusted to meet age-specific glycemic goals throughout course of study.
Study: NCT00564018
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
Study: NCT02877303
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and IV
Study: NCT02877303
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02877303
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02877303
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01597713
Drug: NNC 0148-0000-0362
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
Study: NCT01789125
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01597713
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
Study: NCT01597713
Drug: NNC 0148-0000-0362
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
Study: NCT01597713
Drug: NNC 0148-0000-0362
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
Study: NCT01597713
Drug: NNC 0148-0000-0362
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
Study: NCT02259907
Drug: KUC 7483 CL
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03969329
Drug: Etelcalcetide
Normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
Study: NCT03441048
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine is a purine antimetabolite.
Study: NCT03441048
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine is an antineoplastic anti-metabolite.
Study: NCT03441048
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone is an anthracenedione antineoplastic agent.
Study: NCT03441048
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
Study: NCT00761696
Drug: IPI-926
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral daily dosing
Study: NCT03688464
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Study: NCT03905135
Drug: rhIL-15
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
Study: NCT03905135
Drug: rhIL-15
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
Study: NCT01870505
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01870505
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06094790
Drug: CORT125134 150 mg
Normalized name: CORT125134
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125134 150 mg (3 X 50 mg current capsule formulation)
Study: NCT06094790
Drug: CORT125134 250 mg
Normalized name: CORT125134
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125134 250 mg (5 X 50 mg current capsule formulation)
Study: NCT06094790
Drug: CORT125134 dose to be determined
Normalized name: olopatadine
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CORT125134 current capsule formulation, dose to be determined
Study: NCT04523181
Drug: Antroquinonol
Normalized name: Antroquinonol
DrugBank: Antroquinonol (DB12326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-blind for antroquinonol and Placebo with same out-look and same frequency.
Study: NCT00528892
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: switching PI to raltegravir
Study: NCT00528892
Drug: boosted PI
Normalized name: PI-103
DrugBank: PI-103 (DB17046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: continue on boosted-PI
Study: NCT03200340
Drug: EC-18
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of EC-18 twice daily
Study: NCT02225834
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
Study: NCT02783183
Drug: Lyrica
Normalized name: Lyrica
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 by 2
Study: NCT01720719
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atorvastatin 20mg, qd, for 24 weeks
Study: NCT02423239
Drug: Dexanabinol
Normalized name: Dexanabinol
DrugBank: Dexanabinol (DB06444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
Study: NCT02423239
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
Study: NCT02423239
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
Study: NCT01720719
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vitamin E 300mg, qd, for 24 weeks
Study: NCT02423239
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
Study: NCT00207129
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
Study: NCT02374021
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gm bid
Study: NCT02374021
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg twice daily, not to exceed 6.5mg/kg
Study: NCT02374021
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg SC weekly
Study: NCT03068754
Drug: Acthar
Normalized name: Acthar
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repository corticotropin for subcutaneous injection
Study: NCT02374021
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg SQ every other week
Study: NCT00724295
Drug: peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
Study: NCT00724295
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
Study: NCT01073202
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
Study: NCT01073202
Drug: identical-appearing placebo
DrugBank: Pear (DB10554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
Study: NCT02599779
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
Study: NCT05138913
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the arthroscopic operation was completed, a local saline injection was performed
Study: NCT03794154
Drug: Cymbalta capsule
Normalized name: Cymbalta
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
Study: NCT03794154
Drug: Duloxetine hydrochloride capsule
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
Study: NCT01201187
Drug: YY-162
Normalized name: Peptide YY
DrugBank: Peptide YY (3-36) (DB05004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
Study: NCT00303849
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IA
Study: NCT02822261
Drug: Coppertone (BAY987516)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-66_R84-088)
Study: NCT00303849
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00303849
Drug: Etoposide Phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00303849
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IA
Study: NCT00303849
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IA
Study: NCT00303849
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04676035
Drug: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27
Study: NCT02781584
Drug: SEL
Normalized name: Selen
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02781584
Drug: CILO
Normalized name: Ciloxan
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02781584
Drug: FENO
Normalized name: Fenol
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02496910
Drug: Telmisartan/Amlodipine 80/5 mg (FDC)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04146935
Drug: Burosumab Injection [Crysvita]
Normalized name: burosumab Injection [Crysvita]
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Burosumab/Crysvita SC injection monthly
Study: NCT03533244
Drug: Vehicle Eye Drops
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop, three times daily to the study eye for 28 days
Study: NCT00612196
Drug: TB-402
Normalized name: TB-402
DrugBank: TB-402 (DB06050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
Study: NCT00273429
Drug: timolol maleate 0.5%
Normalized name: TIMOLOL MALEATE 0.5% GEL,OPH
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00273429
Drug: dorzolamide/timolol maleate fixed combination
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00273429
Drug: latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00242996
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00242996
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01196416
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01196416
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01196416
Drug: Vinblastine Sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01870726
Drug: Buparlisib
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
Study: NCT00085891
Drug: Quetiapine Fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00315016
Drug: fosinopril
Normalized name: Fosinopril
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doubling of fosinopril dose
Study: NCT02075411
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block
Study: NCT02075411
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block
Study: NCT03430232
Drug: STR-324 Dose Level 1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level 2
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level 3
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level 4
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level 5
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level 6
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level 7
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level 8
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion of a solution for intravenous administration
Study: NCT03430232
Drug: STR-324 Dose Level A
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long infusion of a solution for intravenous administration
Study: NCT00633061
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children \>2 months and 1.5 mg/kg every 12 hours for infants \<2 months. Duration of treatment is 6 weeks.
Study: NCT02827136
Drug: Lidocaine patch and hypafix
Normalized name: lidocaine Medicated Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
Study: NCT01248949
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.